On September 8, 2026, Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation for its lead asset, QRX003, to treat Peeling Skin Syndrome. This marks the second such designation for QRX003, following a prior grant for Netherton Syndrome. The company stated it expects to initiate a Phase 2 clinical study before the end of 2026, planning to enroll up to 12 pediatric and adult patients in the U.S. and Europe under an open Investigational New Drug application. Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases.

Quoin Pharmaceuticals announced a private placement raising up to $50.0 million in gross proceeds, comprising an initial $30.8 million and up to $19.2 million from the potential cash exercise of accompanying warrants. The company issued 6,305,300 American Depositary Shares (ADSs) or pre-funded warrants at a combined price of $4.88 per unit, alongside ordinary warrants exercisable at $6.10 per ADS for up to 3,152,650 additional ADSs. Net proceeds are expected to fund operations into the second half of 2029. Additionally, Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, where four of six participants met the primary endpoint with statistical significance (p=0.0087). The company also settled approximately $1.15 million in accrued debt by issuing 222,574 ADSs to note holders. Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases.

On June 23, 2026, Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) conditionally approved QYLEKI™ as the proposed brand name for QRX003. QRX003 is an investigational product candidate intended for the treatment of Netherton Syndrome. The company plans to include a request for final proprietary name approval for QYLEKI within its upcoming New Drug Application (NDA) for QRX003. Quoin Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases.